# CALL FOR PROPOSALS

### Letter of Intent Application Form

The completed Letter of Intent (LOI) application must be delivered by email to [applications@biocanrx.com](mailto:applications@biocanrx.com) and must be received by 11:59 am ET, on the deadline in advance of the next scheduled RMC meeting (see [Apply for funding](http://www.biocanrx.com/apply-for-funding/) on the BioCanRx website).

Please direct questions about the program and application process to Kelley Parato (BioCanRx Director, Scientific Affairs, [keparato@biocanrx.com](mailto:keparato@biocanrx.com), (613) 739-6595) or Stéphanie Michaud (BioCanRx President and Chief Executive Officer, [smichaud@biocanrx.com](mailto:smichaud@biocanrx.com) (613) 739-6202).

### Document 1

Please complete the Letter of Intent Application Form in single-spaced type, Times New Roman or Arial (minimum 11 pt font), with one-inch margins. Please enter the project leader’s name in the header but do not modify the rest of the header. You may delete the specific section instructions but do not delete section headings. The file name should include the Project Leader’s name and date (e.g. Bell\_LOI\_April 2\_2017.pdf), and be saved in PDF format.

### Section 1: Project Overview

**Project Title:**

**Funding Opportunity (only 1 funding program per LOI application)**

**🞏 Clinical Trial Program**

**🞏 Enabling Studies Program**

**🞏 Catalyst Program**

**🞏 Clinical, Social and Economic Impact Program**

**🞏 Core Facilities Program**

**Project Leader:** Identify one network investigator who will be responsible for overseeing management of the project, including allocation of project budgets and progress reporting to BioCanRx. Also indicate the host institution.

**Projected BioCanRx Budget request:**

**Requested Period of Support:** (dd/mm/yyyy) to (dd/mm/yyyy): Pick a period that most accurately reflects the expected time over which the project will be conducted.

**Project Description**: Using **lay language** only, and in no more than 250 words, describe the current unmet clinical need or BioCanRx technology to which the proposed project applies, and make the case for BioCanRx to fund it. Note: This description may be posted on the BioCanRx website, or used in BioCanRx communications material targeted at potential donors or partners.

**Relevance and Impact:** In no more than 250 words, highlight the anticipated impact of this project within the cancer biotherapeutics scientific community or within the technology portfolio of BioCanRx, focusing particularly on how the project is relevant to the BioCanRx mission.

**Key Deliverables:** Identify key project deliverables (a bulleted list with one or two sentences detailing each deliverable).

### Section 2: Project Team & Roles

**Team Members:** In Table I below, list all proposed investigators involved in the project, including Principal Investigators (PIs) requesting BioCanRx funding, co-investigators not requesting BioCanRx funding, and collaborators (international collaborators, industry collaborators, project stakeholders) not funded by BioCanRx. For each person, provide their name, position, institutional affiliation and email address. Do not include trainees and personnel.

For all Network Investigators requesting funding, and project co-investigators not requesting funding, attach a free-form **abridged CV, 2 pages maximum**. The CVs accompanying LOI submissions should include: contact information, current position(s)/ appointment(s)/affiliation(s), current funding sources (source, title, amount, funding period), and publications in the last 5 years, relevant to the proposed research.

#### Table I: Project Investigators

Indicate Principal Investigators (PIs) participating in the project, including collaborators not funded by BioCanRx. In the “Portion of total working time committed to project” input value as either hours/week OR %.  Be sure to include the appropriate unit.

|  |  |  |
| --- | --- | --- |
| **Principal Investigator & Institution** | **Role in Project/Expertise** | **Portion of total working time committed to project** (hrs/week or %; be sure to include the appropriate unit) |
| Principal investigators (receiving BioCanRx funds) | | |
| Name, position, institution, email address |  |  |
|  |  |  |
|  |  |  |
| Co-Investigators (not receiving BioCanRx funds) | | |
| Name, position, institution, email address |  |  |
|  |  |  |
|  |  |  |
| Industry collaborators | | |
| Name, position, institution, email address |  |  |
|  |  |  |
|  |  |  |
| International collaborators | | |
| Name, position, institution, email address |  |  |
|  |  |  |
|  |  |  |
| Project stakeholders | | |
| Name, position, institution, email address |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

### Section 3: Scientific Summary

In two (2) pages maximum:

1. Describe the background, rationale and objectives of the project.
2. Highlight the international competitiveness and innovative nature of the proposed technology. Also provide comment on potential technological, clinical and/or commercial impact of the proposed project. **Highlight the contribution of the proposed work to the advancement of BioCanRx technology(ies).**
3. Figures, tables and references may be added to a maximum of two (2) pages.

### Section 4: Partnerships

In the Table II below (adding lines as necessary), list each partner that is anticipated to support the proposed project. Detail the amount ($) and nature of support anticipated. It is expected that each Catalyst, Enabling, or Clinical, Social and Economic Impact project will secure 50% of total project funds from partner sources, while Clinical Trial projects are expected to secure 60% of required funds from partners. Not all of this funding needs to be secured at the time of submission of the LOI. Letters from partners indicating the nature of their involvement in the project and their anticipated contribution are recommended at the LOI phase, and should be addressed to BioCanRx, and appended at the end of the application document. Partner letters are **required** at the Full Application phase. Please note that the three federal granting councils (CIHR, NSERC and SSHRC), other NCEs, CFI and Genome Canada are not eligible partners for the purpose of this competition. Please refer to the BioCanRx Policy on Industry-Partnered Research in preparation of your application.

#### Table II: Partners

|  |  |  |
| --- | --- | --- |
| Name of Partner | Value of Contribution ($CAD) | Cash/In-Kind (detail) |
| 1. |  |  |
| Role in Project:  Potential Conflict of Interest? | | |
| 2. |  |  |
| Role in Project:  Potential Conflict of Interest? | | |
| 3. |  |  |
| Role in Project:  Potential Conflict of Interest? | | |
| 4. |  |  |
| Role in Project:  Potential Conflict of Interest? | | |

### Section 5: Future Product/Platform Development Trajectory

A key objective of BioCanRx funding is to accelerate the translation of cancer biotherapeutic innovations from the laboratory through to early phase clinical evaluation, with the ultimate goal of delivering products and platforms for commercialization, and market access to cancer patients. In **250 words maximum**, describe the anticipated next steps in technological advancement or clinical and/or commercial development of the product(s) and/or platform(s) in the proposed study. Describe the intellectual property status of the technology, and include a realistic assessment of the likelihood of industry partner engagement and the role of prospective partners in future development of your product/platform. Also, discuss any additional partners from other sectors (NGO, consortia), which might be required to realize these later stage development goals.